drugset / Trial / NCT02558829

Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency

NCT02558829

Phase 3 Completed 157 enrolled AEterna Zentaris
RandomizedCrossoverOpen-labelDiagnostic

Summary

The Macimorelin Growth Hormone Stimulation Test (GHST) will be compared with the Insulin Tolerance Test (ITT) in an open-label, randomized, 2-way crossover Trial. The trial will include subjects suspected to have adult growth hormone deficiency (AGHD) and a group of healthy control subjects.

Timeline

Start
2015-12-03
Primary completion
2016-11-29
Completion
2016-11-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic 0.1 iu/kg Intravenous
Subject Insulin Protein / enzyme biologic 0.15 iu/kg Intravenous
Subject Macimorelin Small molecule 0.5 mg/kg Oral

Indications